| Duvelisib studied in …STUDIED_INderived42 of 42show fewer |
|---|
| → studied in | NCT05057247Phase 2 · completed Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC · 42 trials list this drug (13 active) | — | — | Malignant Head and Neck Neoplasm,Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05044039Phase 1 · active not recruiting Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy · 42 trials list this drug (13 active) | — | — | Acute Lymphoblastic Leukemia,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05010005Phase 1 · recruiting A Study of Ruxolitinib and Duvelisib in People With Lymphoma · 42 trials list this drug (13 active) | — | — | T-Cell Large Granular Lymphocyte Leukemia,T-Cell Non-Hodgkin Lymphoma,T-Cell Prolymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04803201Phase 2 · recruiting Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma · 42 trials list this drug (13 active) | — | — | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma,Follicular Helper T-Cell Lymphoma,Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07293403Phase 2 · recruiting Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas · 42 trials list this drug (13 active) | — | — | Follicular Helper T-Cell Lymphoma,Peripheral T-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04652960Phase 1 · active not recruiting Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome · 42 trials list this drug (13 active) | — | — | Mycosis Fungoides and Sezary Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07714187Phase 1 · not yet recruiting A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides · 42 trials list this drug (13 active) | — | — | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma,Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06810778Phase 1/Phase 2 · recruiting Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) · 42 trials list this drug (13 active) | — | — | T-Cell Prolymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07001384Phase 1 · recruiting A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL) · 42 trials list this drug (13 active) | — | — | Anaplastic Large Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04331119Phase 2 · terminated Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas · 42 trials list this drug (13 active) | — | — | T-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02783625Phase 1 · completed Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas · 42 trials list this drug (13 active) | — | — | Lymphoma,T-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06522737Phase 3 · recruiting A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype · 42 trials list this drug (13 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03534323Phase 1/Phase 2 · active not recruiting Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS · 42 trials list this drug (13 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02158091Phase 1/Phase 2 · active not recruiting A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL · 42 trials list this drug (13 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03961672Phase 2 · active not recruiting Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · 42 trials list this drug (13 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04688658Phase 1/Phase 2 · terminated Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma · 42 trials list this drug (13 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05065866Phase 1 · completed Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy · 42 trials list this drug (13 active) | — | — | Hodgkin Lymphoma,Lymphoid Leukemia,Multiple Myeloma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03372057Phase 2 · completed A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) · 42 trials list this drug (13 active) | — | — | Peripheral T-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04890236early Phase 1 · completed Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study · 42 trials list this drug (13 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04038359Phase 2 · completed A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma · 42 trials list this drug (13 active) | — | — | Indolent Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03892044Phase 1 · completed Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma · 42 trials list this drug (13 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma,Diffuse Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05923502not yet recruiting (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) · 42 trials list this drug (13 active) | — | — | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Diffuse Large B-Cell Lymphoma,Follicular Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02204982Phase 3 · terminated Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma · 42 trials list this drug (13 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02391545Phase 1/Phase 2 · terminated A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO) · 42 trials list this drug (13 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02004522Phase 3 · completed A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) · 42 trials list this drug (13 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02049515Phase 3 · completed A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 · 42 trials list this drug (13 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04193293Phase 1/Phase 2 · terminated A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer · 42 trials list this drug (13 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02711852Phase 2 · completed A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145) · 42 trials list this drug (13 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01882803Phase 2 · completed A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma · 42 trials list this drug (13 active) | — | — | Indolent Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03370185Phase 2 · withdrawn Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma · 42 trials list this drug (13 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04639843Phase 1 · withdrawn Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma · 42 trials list this drug (13 active) | — | — | Adult T-Cell Leukemia/Lymphoma,Hepatosplenic T-Cell Lymphoma,Enteropathy-Associated T-Cell Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05508659Phase 1/Phase 2 · unknown A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors · 42 trials list this drug (13 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04836832Phase 1 · withdrawn Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma · 42 trials list this drug (13 active) | — | — | Follicular Lymphoma,Indolent Non-Hodgkin Lymphoma,Splenic Marginal Zone Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04209621Phase 2 · terminated Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · 42 trials list this drug (13 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02576275Phase 3 · withdrawn A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) · 42 trials list this drug (13 active) | — | — | Small Lymphocytic Lymphoma,Follicular Lymphoma,Indolent Non-Hodgkin Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02605694Phase 2 · withdrawn Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO) · 42 trials list this drug (13 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04342117terminated Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL · 42 trials list this drug (13 active) | — | — | Lymphoma,Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04707079Phase 2 · unknown A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma · 42 trials list this drug (13 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02598570Phase 1 · completed Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma · 42 trials list this drug (13 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02640833Phase 1 · withdrawn A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor · 42 trials list this drug (13 active) | — | — | Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01871675Phase 1 · completed Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies · 42 trials list this drug (13 active) | — | — | Lymphoma,Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02028039Phase 2 · withdrawn IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) · 42 trials list this drug (13 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |